triazoles has been researched along with bryostatin 1 in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Bullen, CK; Durand, CM; Laird, GM; Siliciano, JD; Siliciano, RF | 1 |
| Bullen, CK; Durand, CM; Hill, AL; Laird, GM; Martin, AR; Rosenbloom, DI; Siliciano, JD; Siliciano, RF | 1 |
| Álvarez, S; Clemente, MI; Díaz, L; García-Alonso, D; Martínez-Bonet, M; Moreno, S; Muñoz, E; Muñoz-Fernández, MÁ | 1 |
| Fu, M; Gong, L; He, H; Li, H; Wang, TT | 1 |
| Barat, C; Drouin, J; Leboeuf, M; Proust, A; Tremblay, MJ | 1 |
| Barat, C; Drouin, J; Gagnon, MT; Leboeuf, M; Proust, A; Tremblay, MJ; Vanasse, F | 1 |
| Akari, H; Irie, K; Kikumori, M; Murata, M; Seki, Y; Tan, W; Tang, Y; Wardani, NP; Washizaki, A | 1 |
7 other study(ies) available for triazoles and bryostatin 1
| Article | Year |
|---|---|
New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo.
Topics: Anti-HIV Agents; Azepines; Bryostatins; CD4-Positive T-Lymphocytes; Cell Cycle Proteins; Depsipeptides; Disulfiram; Histone Deacetylase Inhibitors; HIV Infections; HIV-1; Humans; Hydroxamic Acids; Indoles; Ionomycin; Lymphocyte Activation; Nuclear Proteins; Panobinostat; Tetradecanoylphorbol Acetate; Transcription Factors; Triazoles; Virus Latency; Vorinostat | 2014 |
Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations.
Topics: Adult; Anti-HIV Agents; Azepines; Bryostatins; CD4-Positive T-Lymphocytes; Cells, Cultured; Disulfiram; Drug Evaluation, Preclinical; Drug Synergism; Female; Histone Deacetylase Inhibitors; HIV Infections; HIV-1; Humans; Lymphocyte Activation; Lymphokines; Male; Middle Aged; Phorbol Esters; Protein Kinase C; RNA, Messenger; RNA, Viral; Transcription, Genetic; Triazoles; Virion; Virus Latency | 2015 |
Antiretroviral drugs do not interfere with bryostatin-mediated HIV-1 latency reversal.
Topics: Adult; Anti-Retroviral Agents; Bryostatins; CD4-Positive T-Lymphocytes; Cells, Cultured; Cyclohexanes; Drug Interactions; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV-1; Humans; Male; Maraviroc; Middle Aged; Triazoles; Virus Latency | 2015 |
Short Communication: Preferential Killing of HIV Latently Infected CD4(+) T Cells by MALT1 Inhibitor.
Topics: Acetanilides; Bryostatins; Caspases; CD4-Positive T-Lymphocytes; Cell Line, Tumor; HIV Infections; HIV-1; Humans; Jurkat Cells; Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Protein; Neoplasm Proteins; Ribonucleases; Transcription Factors; Triazoles; Virus Activation; Virus Latency; Virus Replication | 2016 |
Contrasting effect of the latency-reversing agents bryostatin-1 and JQ1 on astrocyte-mediated neuroinflammation and brain neutrophil invasion.
Topics: Adjuvants, Immunologic; Astrocytes; Azepines; Brain; Bryostatins; Chemotaxis, Leukocyte; HIV-1; Humans; Inflammation; Neutrophils; Triazoles; Virus Activation; Virus Latency | 2017 |
HIV-1 infection and latency-reversing agents bryostatin-1 and JQ1 disrupt amyloid beta homeostasis in human astrocytes.
Topics: Amyloid beta-Peptides; Astrocytes; Azepines; Bryostatins; HIV Infections; HIV-1; Homeostasis; Humans; Triazoles; Virus Activation; Virus Latency | 2020 |
The Novel PKC Activator 10-Methyl-Aplog-1 Combined with JQ1 Induced Strong and Synergistic HIV Reactivation with Tolerable Global T Cell Activation.
Topics: Anti-HIV Agents; Azepines; Bryostatins; CD4-Positive T-Lymphocytes; Cell Line; HIV Infections; HIV-1; Humans; Lymphocyte Activation; Phorbol Esters; Signal Transduction; Triazoles; Virus Latency | 2021 |